In PD, it has long been known that LRRK2 mutations (in particular G2019S) lead to an increased kinase activity and this upregulation is currently being targeted by LRRK2 kinase inhibitors as a therapeutic agent in PD10–12. Here, LRRK2 is linked to Parkinson disease.